Physician profile
Peter P Chan
NPI 1134160708
$9,429.51
in general payments reported to CMS, 2019-2025
38 companies · $2,091 in 2025
The $2,091 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,513 · 2020: $854 · 2021: $451 · 2022: $1,139 · 2023: $1,621 · 2024: $1,761 · 2025: $2,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,472.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,476.40 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,171.22 | 2019-2025 | |
| Lilly USA, LLC | $1,168.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $815.82 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $559.95 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $513.54 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $395.91 | 2019-2025 | Qulipta, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.80 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $366.46 | 2019-2023 | M-M-R II, Vaxelis, Rotateq |
| Amgen INC. | $356.59 | 2019-2023 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $356.33 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $261.60 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $194.00 | 2019-2025 | |
| Amarin Pharma, INC. | $167.61 | 2019-2021 | |
| Dexcom, INC. | $144.84 | 2022-2025 | Dexcom G6 Transmitter |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.